AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3225427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefamandole and oral cephalexin
Number of subjects: 87
Study 3225427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous and oral)
Number of subjects: 87
Study 31793099 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction methods (3D videos with VR goggles and optical illusion pictures)
Number of subjects: 120
Study 31793099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 30579131 — intervention group
Group type: COMPARATOR
Intervention: Mindfully attending externally to the feared object (Ext)
Number of subjects: 48
Study 30579131 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to both the object and their internal distress (Int/Ext)
Number of subjects: 48
Study 28383710 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8477 (20/30 mg BID)
Number of subjects: 132
Study 28383710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 28383710 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8477
Number of subjects: 132
Study 25257259 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Tyrosine (TYR) supplement
Number of subjects: 0
Study 25257259 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 24171985 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR membrane + bone graft (test)
Number of subjects: 20
Study 24171985 — intervention group
Group type: COMPARATOR
Intervention: OFD (control)
Number of subjects: 20
Study 22355992 — intervention group
Group type: EXPERIMENTAL
Intervention: High Voltage Pulsed Galvanic Stimulation (HVPGS)
Number of subjects: 33
Study 22355992 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) technique
Number of subjects: 33
Study 19162114 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 co-administered with OPV
Number of subjects: 0
Study 19162114 — intervention group
Group type: COMPARATOR
Intervention: Placebo co-administered with OPV
Number of subjects: 0
Study 19162114 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 without OPV
Number of subjects: 0
Study 19162114 — intervention group
Group type: COMPARATOR
Intervention: Placebo without OPV
Number of subjects: 0
Study 17290044 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum measurement
Number of subjects: 57
Study 15566914 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 102
Study 15566914 — intervention group
Group type: COMPARATOR
Intervention: Off-pump left internal mammary artery bypass grafting
Number of subjects: 102
Study 12362748 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10446946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose 9 to 11 mmol/L)
Number of subjects: 10
Study 10446946 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan administration during hyperglycemia
Number of subjects: 10
Study 10446946 — intervention group
Group type: EXPERIMENTAL
Intervention: AngII infusion (1.5 ng/kg per min) during hyperglycemia
Number of subjects: 10
Study 10446946 — intervention group
Group type: EXPERIMENTAL
Intervention: AngII infusion
Number of subjects: 10
Study 10446946 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (blood glucose 4 to 6 mmol/L)
Number of subjects: 10
Study 8683087 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPs with < 4 years of surveillance experience
Number of subjects: 16
Study 8683087 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPs with >= 4 years of surveillance experience
Number of subjects: 16
Study 8683087 — intervention group
Group type: COMPARATOR
Intervention: All ICP-years observed
Number of subjects: 16
Study 2223359 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% end‐tidal isoflurane
Number of subjects: 20
Study 2223359 — intervention group
Group type: COMPARATOR
Intervention: 0.5% halothane
Number of subjects: 20
Study 667192 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback group
Number of subjects: 20
Study 667192 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 30676648 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuation instructions for recognizing other-age faces
Number of subjects: 0
Study 30676648 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization task performance
Number of subjects: 0
Study 28863912 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-premolar extraction protocol in Class II malocclusion patients
Number of subjects: 105
Study 28863912 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-premolar extractions in Class II malocclusion patients
Number of subjects: 105
Study 28863912 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-premolar extractions in Class I malocclusion patients
Number of subjects: 105
Study 25864723 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intubated state (conscious sedation)
Number of subjects: 0
Study 25864723 — intervention group
Group type: COMPARATOR
Intervention: Intubated state (general anesthesia)
Number of subjects: 0
Study 23721753 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt abdominal entry
Number of subjects: 15935
Study 23721753 — intervention group
Group type: COMPARATOR
Intervention: Sharp abdominal entry
Number of subjects: 15935
Study 23721753 — intervention group
Group type: EXPERIMENTAL
Intervention: Exteriorisation of the uterus for repair
Number of subjects: 15935
Study 23721753 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal repair
Number of subjects: 15935
Study 23721753 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer closure of the uterus
Number of subjects: 15935
Study 23721753 — intervention group
Group type: COMPARATOR
Intervention: Double-layer closure of the uterus
Number of subjects: 15935
Study 23721753 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 15935
Study 23721753 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of the peritoneum
Number of subjects: 15935
Study 23721753 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromic catgut for uterine repair
Number of subjects: 15935
Study 23721753 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin-910 for uterine repair
Number of subjects: 15935
Study 21843028 — intervention group
Group type: EXPERIMENTAL
Intervention: Quixfil (QF)
Number of subjects: 36
Study 21843028 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme (FS)
Number of subjects: 36
Study 21843028 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Silorane (SI)
Number of subjects: 36
Study 21843028 — intervention group
Group type: EXPERIMENTAL
Intervention: LED Bluephase C8 (LED)
Number of subjects: 36
Study 21843028 — intervention group
Group type: COMPARATOR
Intervention: Halogen Translux Energy (HTE)
Number of subjects: 36
Study 19661833 — intervention group
Group type: EXPERIMENTAL
Intervention: EPP followed by radical hemithorax radiotherapy
Number of subjects: 50
Study 19661833 — intervention group
Group type: COMPARATOR
Intervention: Continued best care
Number of subjects: 50
Study 17944641 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction (LTS II)
Number of subjects: 100
Study 17944641 — intervention group
Group type: COMPARATOR
Intervention: LMA-ProSeal
Number of subjects: 100
Study 15569162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed cryoprecipitate stored for 6 h at room temperature
Number of subjects: 37
Study 15569162 — intervention group
Group type: EXPERIMENTAL
Intervention: Type ORh+ blood
Number of subjects: 37
Study 15569162 — intervention group
Group type: EXPERIMENTAL
Intervention: Units stored <6 months
Number of subjects: 37
Study 15569162 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriological culture studies
Number of subjects: 37
Study 11739302 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides >200 mg/dL
Number of subjects: 11177
Study 11739302 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% decrease in %HDL
Number of subjects: 11177
Study 11739302 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides
Number of subjects: 11177
Study 11739302 — intervention group
Group type: EXPERIMENTAL
Intervention: High %HDL
Number of subjects: 11177
Study 9166835 — intervention group
Group type: EXPERIMENTAL
Intervention: VNCOP-B plus G-CSF
Number of subjects: 149
Study 9166835 — intervention group
Group type: COMPARATOR
Intervention: VNCOP-B alone (Control)
Number of subjects: 149
Study 1586330 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (3mg) gel
Number of subjects: 59
Study 1586330 — intervention group
Group type: COMPARATOR
Intervention: Sterile K‐Y Jelly
Number of subjects: 59
Study 3896614 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view mammography screening (ASP)
Number of subjects: 0
Study 3896614 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31484579 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARECONTRACEPT decision-making tool
Number of subjects: 1708
Study 31484579 — intervention group
Group type: COMPARATOR
Intervention: Conventional contraceptive counselling
Number of subjects: 1708
Study 28159826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive titration of vasoactive HF therapies
Number of subjects: 38
Study 25487877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripasudil 0.2%
Number of subjects: 28
Study 25487877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripasudil 0.4%
Number of subjects: 28
Study 25487877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23323969 — intervention group
Group type: EXPERIMENTAL
Intervention: Super taster (ST) or Sweet liker (SL)
Number of subjects: 196
Study 23323969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet liker (SL) + Super taster (ST)
Number of subjects: 196
Study 21107513 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell training (ballistic full‐body kettlebell exercise 3 times per week for 8 weeks)
Number of subjects: 40
Study 21107513 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19728940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hasson cannula
Number of subjects: 120
Study 19728940 — intervention group
Group type: COMPARATOR
Intervention: Veress needle
Number of subjects: 120
Study 17214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace safety programs
Number of subjects: 0
Study 17214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety training
Number of subjects: 0
Study 17214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to safety
Number of subjects: 0
Study 17214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety classes and training
Number of subjects: 0
Study 17214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated safety teams/individuals
Number of subjects: 0
Study 17214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect costs of workplace injury
Number of subjects: 0
Study 17214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Investment in workplace safety
Number of subjects: 0
Study 14998098 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled soccer and field hockey players
Number of subjects: 0
Study 14998098 — intervention group
Group type: COMPARATOR
Intervention: Skilled soccer, field hockey, and volleyball players
Number of subjects: 0
Study 14998098 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled field hockey and soccer players
Number of subjects: 0
Study 14998098 — intervention group
Group type: EXPERIMENTAL
Intervention: Less skilled participants
Number of subjects: 0
Study 11378012 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (beta-blocker)
Number of subjects: 0
Study 11378012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy
Number of subjects: 0
Study 11378012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous non-selective endothelin antagonist
Number of subjects: 0
Study 11378012 — intervention group
Group type: COMPARATOR
Intervention: Cardioversion
Number of subjects: 0
Study 11378012 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (TNF receptor analogue)
Number of subjects: 0
Study 9131947 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose inhalation of fluticasone propionate (1000 micrograms)
Number of subjects: 12
Study 9131947 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated inhalations of fluticasone propionate (1000 micrograms twice daily for 7 days)
Number of subjects: 12
Study 9131947 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dose of fluticasone propionate (20 micrograms) as a reference
Number of subjects: 12
Study 8111807 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230
Study 8111807 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine-ER
Number of subjects: 230
Study 3298405 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) at 45 mg/kg/day by continuous infusion for 28 days
Number of subjects: 20
Study 3298405 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) at 45 mg/kg/day by intermittent 8-hourly infusion for 28 days
Number of subjects: 20
Study 3298405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3298405 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) treatment
Number of subjects: 20
Study 2583756 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (120 mg elemental iron as ferrous sulphate daily)
Number of subjects: 110
Study 2583756 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (240 mg elemental iron as ferrous sulphate daily)
Number of subjects: 110
Study 2583756 — intervention group
Group type: COMPARATOR
Intervention: Group A (60 mg elemental iron as ferrous sulphate daily)
Number of subjects: 110
Study 31615182 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Number of subjects: 80
Study 31615182 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 80
Study 28800039 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored intelligent physical exercise training (IPET) - 1 hour high-intensity once a week, plus 30 minutes moderate-intensity physical activity 6 days a week during leisure-time
Number of subjects: 387
Study 28800039 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 387
Study 25500684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate (20 mg/kg)
Number of subjects: 80
Study 25500684 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg/1 ml)
Number of subjects: 80
Study 25500684 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 80
Study 25500684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate
Number of subjects: 80
Study 24001246 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with monetary vouchers for stimulant-negative urine samples
Number of subjects: 82
Study 21521543 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-containing functional food (DHA-FF)
Number of subjects: 47
Study 21521543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19234078 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of depression, moodiness, and prior appointment avoidance due to fear
Number of subjects: 357
Study 19234078 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported anxiety or nervousness
Number of subjects: 357
Study 16585858 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric tissue reduction (RFVTR)
Number of subjects: 19
Study 16585858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12777542 — intervention group
Group type: EXPERIMENTAL
Intervention: Media education campaign
Number of subjects: 1500
Study 12777542 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization strategy
Number of subjects: 1500
Study 12777542 — intervention group
Group type: COMPARATOR
Intervention: Control area
Number of subjects: 1500
Study 12777542 — intervention group
Group type: EXPERIMENTAL
Intervention: Media campaign
Number of subjects: 1500
Study 10867294 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement intervention session
Number of subjects: 41
Study 10867294 — intervention group
Group type: COMPARATOR
Intervention: Standard anger management classes
Number of subjects: 41
Study 9197957 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent solutions at 37 degrees C
Number of subjects: 0
Study 9197957 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent solutions at 40 degrees C
Number of subjects: 0
Study 9197957 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent with higher anionic content at both temperatures
Number of subjects: 0
Study 9197957 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent with lower anionic content at both temperatures
Number of subjects: 0
Study 1609940 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 71
Study 1609940 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 71
Study 1609940 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pethidine
Number of subjects: 71
Study 4029895 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 35
Study 4029895 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (equivalent dose to metoclopramide)
Number of subjects: 35
Study 4029895 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg) with spironolactone (300 mg/day)
Number of subjects: 35
Study 4029895 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (equivalent dose to metoclopramide) with spironolactone (300 mg/day)
Number of subjects: 35
Study 29676944 — intervention group
Group type: EXPERIMENTAL
Intervention: CTS5 (Clinical Treatment Score post-5 years)
Number of subjects: 11846
Study 29676944 — intervention group
Group type: EXPERIMENTAL
Intervention: CTS5 risk stratification
Number of subjects: 11846
Study 29676944 — intervention group
Group type: EXPERIMENTAL
Intervention: Final CTS5 algorithm
Number of subjects: 11846
Study 27749954 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg) plus 5 doses of 100 mL decaffeinated coffee (total 500 mg caffeine)
Number of subjects: 51
Study 27749954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose capsules) plus 5 doses of 100 mL decaffeinated coffee
Number of subjects: 51
Study 27749954 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion with higher plasma caffeine concentration
Number of subjects: 51
Study 24002341 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed Treadmill Training (TT)
Number of subjects: 34
Study 24002341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Treadmill Training (TT)
Number of subjects: 34
Study 24002341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 23131971 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and wellness therapy group (n = 37)
Number of subjects: 74
Study 23131971 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n = 37)
Number of subjects: 74
Study 19944581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol xinafoate (FSC) 100/50 microg twice daily
Number of subjects: 526
Study 19944581 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg twice daily
Number of subjects: 526
Study 18388880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 140
Study 18388880 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement ($12/day)
Number of subjects: 140
Study 18388880 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 140
Study 15736893 — intervention group
Group type: EXPERIMENTAL
Intervention: Florida Probe (FP)
Number of subjects: 20
Study 15736893 — intervention group
Group type: COMPARATOR
Intervention: Manual Probe (MP)
Number of subjects: 20
Study 11448906 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin treatment in patients with HRPC
Number of subjects: 0
Study 11448906 — intervention group
Group type: COMPARATOR
Intervention: Plasma VEGF levels
Number of subjects: 0
Study 9649013 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day plus Ursodeoxycholic acid 600 mg/day (group 1)
Number of subjects: 50
Study 9649013 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid 600 mg/day (group 2)
Number of subjects: 50
Study 8596756 — intervention group
Group type: EXPERIMENTAL
Intervention: Uraemic group (HD treatment)
Number of subjects: 30
Study 8596756 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 2570000 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 10
Study 2570000 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 10
Study 2570000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2570000 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine at 1 h before challenge
Number of subjects: 10
Study 2570000 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine at 2 h before challenge
Number of subjects: 10
Study 2570000 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine at 1 and 2 h before challenge
Number of subjects: 10
Study 1192697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptide glycyl‐L‐alanine and its constituent amino acids
Number of subjects: 0
Study 1192697 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution (150 mmol/l)
Number of subjects: 0
Study 1192697 — intervention group
Group type: EXPERIMENTAL
Intervention: High dipeptide concentrations
Number of subjects: 0
Study 30815700 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal environmental exposures (specific exposures not detailed)
Number of subjects: 0
Study 30815700 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model for estimating maternal genotypes' effect on offspring outcomes
Number of subjects: 0
Study 28367694 — intervention group
Group type: EXPERIMENTAL
Intervention: MTPJ arthrodesis
Number of subjects: 52